潰瘍性大腸炎に対する白血球除去療法(LCAP)の作用メカニズム(<特集>炎症性腸疾患に対するアフェレシスの新展開)

概要

論文の詳細を見る
Leukocytapheresis (LCAP) is an extra-corporeal blood circulation treatment which uses the special designed leukocyte removal column complying polyester non-woven fibers, Cellsorba (Asahi Kasei Kuraray Medical Co., Ltd.). In Japan, LCAP using Cellsorba E type is widely applied as a treatment method for ulcerative colitis (UC), especially for patients with severe flare-up or those refractory to the medications like steroid. Also, by the recent research, it has been reported that LCAP improves the UC patients' pathology through the mechanisms of actions, which is the anti-inflammatory effect, the immunological modulation, and the promotion of tissue repair, by removing leukocytes and platelets from the peripheral blood. In this article, we review and summarize these reports concerning the possible mechanisms of LCAP efficacy for UC patients.
2011-02-28